Validity Of The Ihealth-bp7 And Withings-bp800 Self-measurement Blood Pressure Monitors

Abstract

Blood pressure (BP) control among treated people with hypertension remains poor. Home BP monitoring devices have led to their widespread adoption, and are now consistently utilized for the evaluation and management of hypertension. Classifying individual’s risk associated with BP should be monitored using accurate BP measurement devices. However, little is known about the validity of the newly developed iHealth-BP7 and Withings-BP800 devices. PURPOSE: The purpose of this study is to validate the wireless iHealth-BP7 and Withings-BP800 monitors according to the European Society of Hypertension (ESH) International Protocol revision 2010. METHODS: Data from 11 participants (31.6 ± 2.2 years) were initially examined according to the ESH International Protocol revision 2010 for the validation of BP measuring devices in adults. Participants were asked to sit and relax for 10-15 mins with legs uncrossed, and back supported prior to the test. In all participants, sequential left arm measurements were performed by two trained observers using a mercury sphygmomanometer and one supervisor using the device. Collected data were screened according to the ESH protocol for both systolic BP (SBP) and diastolic BP (DBP). ESH International Protocol requires 33 subjects, but currently only 11 subjects participated in this study. Thus, the adjusted criteria of the protocol were applied to establish the standard for the 11 subjects. RESULTS: The mean differences between the monitor and sphygmomanometer readings were -0.55±3.75 (SBP) and 0.54±3.62 (DBP) for iHealth-BP7 and 3.18±4.37 (SBP) and -0.35±5.42 (DBP) for Withings-BP800. The iHealth-BP7 monitor passed all of the modified requirements, however the Withings-BP800 did not meet the last phase of the modified criteria of the ESH international protocol. CONCLUSION: The iHealth-BP7 monitor is recommended as a valid home BP monitoring device, however the Withings-BP800 fails to meet the ESH criteria in this study potentially due to the small sample size. Since the ESH protocol requires 33 subjects, further study with additional participants is warranted to determine validation of both devices.